While i'm glad to hear we submitted our response to the FDA, the fact that we followed six months of silence with a formal letter (vs. speaking to shareholders) is a total joke.
To each his/her own.
I appreciated the formal letter and that it was communication clearly directed at shareholders. It was labeled as a letter to shareholders with the salutation to shareholders. It mentions appreciation to shareholders and their intent to enhance value for all shareholders repeatedly.
Also appreciate the diversity of risk taking/compliance approaches. Love em or hate em-- previous leadership was the opposite side of the risk coin. (As was my feverishly buying at top dollar.) That didn't do us much good. Having a mix of both will be ideal imo.